Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
17 hedge funds and large institutions have $222K invested in Vyant Bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 12 closing their positions.
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
35% less funds holding
Funds holding: 26 → 17 (-9)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
77% less capital invested
Capital invested by funds: $949K → $222K (-$727K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$27.5K |
| 2 |
Renaissance Technologies
New York
|
+$16.5K |
| 3 |
VF
Virtu Financial
New York
|
+$13.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$113K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$24K |
| 3 |
JSC
Jackson Square Capital
San Francisco,
California
|
-$17K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$12K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$12K |
VYNT Hedge Fund Activity: Q4 2022 in Review
17 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2022, worth a combined $222K — down 77% from $949K a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of VYNT and 3 opened new positions — a net loss of 9 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $27.5K. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $113K sold.
- 17 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2022, down from 26 in Q3 2022.
- Funds reported $222K of Vyant Bio, Inc. Common Stock stock for Q4 2022, down 77% quarter-over-quarter.
- 3 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2022 and 12 closed out, a net change of -9 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q4 2022 was HRT Financial, an estimated $27.5K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q4 2022 was CAPTRUST Financial Advisors, an estimated $113K sold.
Based on aggregated 13F filings for Q4 2022.